Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice - Episode 2

Navigating the Heterogeneity of LR-MDS: Importance of Molecular Testing & Risk Stratifying

September 30, 2024

James K. McCloskey, MD, John Theurer Cancer Center, Thomas W. LeBlanc, MD, MA

Panelists discuss how risk stratification tools like IPSS-M are applied in practice for lower-risk myelodysplastic syndromes, addressing prognosis communication and current treatment challenges for this patient group.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Understanding Myelodysplastic Syndromes (MDS): Diagnosis, Classification, and Risk Assessment

Now Viewing

EP. 2: Navigating the Heterogeneity of LR-MDS: Importance of Molecular Testing & Risk Stratifying

EP. 3: Clinical Scenario 1: 76-Year-Old Man With Newly Diagnosed MDS With Symptomatic Anemia, RS Positive

EP. 4: Tailoring Treatment for LR-MDS: Patient Factors, Treatment Goals, and Patient Outcomes

EP. 5: First-Line Luspatercept in LR-MDS: A Deep Dive Into the COMMANDS Trial and Clinical Implications in the Real-Life Practice Setting

EP. 6: Managing Luspatercept Therapy: Dosing, Adverse Effects, and Monitoring

EP. 7: Second-Line LR- MDS Setting: Treatment Options and Considerations

EP. 8: Patient Profile: 66-Year-Old Woman with Newly Diagnosed LR-MDS, RS Negative

EP. 9: Luspatercept Role in the RS-Negative Population and Expert Perspectives on the Role of EPO Levels

EP. 10: First-Line ESA vs Luspatercept in LR-MDS: Choosing the Most Appropriate Treatment Option for Each Individual Patient

EP. 11: Imetelstat and IMerge Trial Review

EP. 12: Looking Ahead in LR-MDS: Future Agents and/or Combination Strategies

EP. 13: The Future of Lower-Risk MDS: Closing Thoughts and Unmet Needs

Video content above is prompted by the following:

Please comment on the risk stratification tools IPSS-M and if you have adapted using this stratification tool in your practice.
What do you are share to your patients in terms of prognosis for those with lower-risk MDS?
What are some current challenges for treating lower-risk MDS?